ACHL News and Press, Achilles Therapeutics plc From 12/21/21

LONDON, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that Iraj Ali, Chief Executive Officer, will present at the virtual 40th Annual J.P. Mo...

LONDON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that the Company has been added to the NASDAQ Biotech Index (Nasdaq: NBI), effective pr...

Ensysce Biosciences (NASDAQ:ENSC) +83%. Inspira Technologies (NASDAQ:IINN) +59%. American Virtual Cloud Technologies (NASDAQ:AVCT) +29% announces significant projected revenue growth of Kandy, its cloud communications platform. Siyata Mobile (NASDAQ:SYTA) +28%. Digital Brands (NASDAQ:DBG...

-Over 10-fold dose increase at GMP scale with VELOS™ Process 2 manufacturing- -cNeT maintain CD4 + and CD8 + T cell subsets with a highly potent polyclonal phenotype- -Dosing of patients with high-dose cNeT expected in 1H 2022- LONDON, Dec. 09, 2021 (GLOBE NEWSW...

Achilles Therapeutics plc (ACHL) SITC & Corporate Update Call November 12, 2021 08:30 AM ET Company Participants Lee Stern - VP, IR & External Communications Iraj Ali - CEO Karl Peggs - CMO Sergio Quezada - CSO Samra Turajlic - Chief Investigator, THETIS Conference Call Participants J...

LONDON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today presented two posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting demonstrat...

Achilles Therapeutics (NASDAQ:ACHL) and Secarna Pharmaceuticals have entered into a research, option and license agreement. Under the terms of the agreement, Secarna will receive an undisclosed upfront payment, a target-based technology access fee as well as option exercise fees. Secarna...

Secarna's LNAplus TM ASOs have the potential to optimize personalized T cell therapies being developed by Achilles Secarna's industry-leading antisense oligonucleotide (ASO) platform LNAplus TM enables discovery and research of ASOs against undisclosed targets in the area of immune o...

Achilles Therapeutics (NASDAQ:ACHL): Q3 GAAP EPS of -$0.34 beats by $0.15. Cash and cash equivalents were $281.9 million as of September 30, 2021, as compared to $177.8 million as of December 31, 2020. Shares -2.33% PM. Press Release For further details see: Achilles Therapeutics E...

- Oral Presentation at European Society for Gene and Cell Therapy (ESGCT) demonstrated ability to generate potent anti-cancer cell therapy candidates in multiple solid tumor types - - Society for Immunotherapy of Cancer (SITC) abstracts highlight the ability to detect, quantify and tr...